Statins and symptomatic chronic systolic heart failure: A post-hoc analysis of 5010 patients enrolled in Val-HeFT

Henry Krum; Roberto Latini; Aldo Maggioni; Inder S. Anand; Serge Masson; Elisa Carretta; Franco Ingrillì; Giacinto Pettinati; Robert Glazer; Gianni Tognoni; Jay N. Cohn

doi:10.1016/j.ijcard.2006.07.106

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2003

The relationship between B-type natriuretic peptide, heart structure, and function in 4,300 patients with heart failure enrolled to Val-HeFT

Roberto Latini, Serge Masson, Lidia Staszewsky, Aldo Maggioni, Alberto Volpi, Simona Barlera, Inder S. Anand, Allen Hester, Maylene Wong, Jay N. Cohn

Article2003

Prognostic Value of Aldosterone in Heart Failure – Results from Val-HeFT

Inder S. Anand, Roberto Latini, Robert Glazer, Allen Hester, Serge Masson, Aldo Maggioni, Nora Aknay, Jay N. Cohn

Article2007

Clinical, Neurohormonal, and Inflammatory Markers and Overall Prognostic Role of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure: Data From the Val-HeFT Heart Failure Trial

Lidia Staszewsky, Maylene Wong, Serge Masson, Simona Barlera, Elisa Carretta, Aldo Maggioni, Inder S. Anand, Jay N. Cohn, Gianni Tognoni, Roberto Latini

Article2005

Valsartan Reduces the Incidence of Atrial Fibrillation in Patients With Heart Failure: Results From the Valsartan Heart Failure Trial (Val-HeFT)

Aldo Maggioni, Roberto Latini, Peter E. Carson

Article2005

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)

Aldo Maggioni, Roberto Latini, Peter E. Carson, Steven Singh, Simona Barlera, Robert Glazer, Serge Masson, E Cerè, Gianni Tognoni, Jay N. Cohn